Showing results (331-340 of 356) with videos related to
Sort By:
Pageof 36
The Lancet. Oncology|March 6, 2017
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, Daniel H Palmer, William Greenhalf, et al.The Lancet. Oncology|April 14, 2022
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trialSyed A Hussain, Jason F Lester, Richard Jackson, et al.Pancreas|December 2, 2014
Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal diclofenacJames A Nicholson, William Greenhalf, Richard Jackson, et al.Journal of the National Cancer Institute|December 1, 2025
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancerDylan Williams, Chandni Patel, Kate Murray, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL studyPhilip J Johnson, Shukui Qin, Joong-Won Park, et al.BMC Cancer|September 18, 2023
Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-scoreThai Ngoc Truong, Trang Ngoc Doan Pham, Long Bao Hoang, et al.JCO Clinical Cancer Informatics|May 12, 2025
Prognostic Significance of the BALAD Serological Model in Systemic Therapies for Hepatocellular Carcinoma: A Personalized Approach to the Prediction of Survival BenefitHidenori Toyoda, Atsushi Hiraoka, Hironori Ochi, et al.Cancers|November 27, 2021
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNAKaren Aughton, Nils O Elander, Anthony Evans, et al.British Journal of Haematology|June 13, 2024
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapyYeong Jer Lim, Victoria Ward, Anthony Brown, et al.Pageof 36